[SGYP] Synergy Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 5.77 Change: 1.03 (21.73%)
Ext. hours: 5.75 Change: -0.02 (-0.35%)

chart SGYP

Refresh chart

Strongest Trends Summary For SGYP

SGYP is in the medium-term down -100% in 1 year. In the long-term down -100% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders, as well as is in Phase IIb clinical trials for the treatment of constipation-predominant irritable bowel syndrome GI disorders. The company also develops SP-333, which is in Phase II clinical trials to treat GI inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-54.85% ROE432.02% ROI
Current Ratio9.53 Quick Ratio Long Term Debt/Equity1.23 Debt Ratio-0.77
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities5.41 M Cash From Investing Activities-50.01 M Cash From Operating Activities-23.15 M Gross Profit
Net Profit-27.39 M Operating Profit-22.8 M Total Assets194.83 M Total Current Assets182.28 M
Total Current Liabilities19.13 M Total Debt200 M Total Liabilities219.57 M Total Revenue
Technical Data
High 52 week2.23 Low 52 week0.07 Last close0.24 Last change-17.21%
RSI42.37 Average true range0.03 Beta0.79 Volume31.45 M
Simple moving average 20 days-22.7% Simple moving average 50 days-1.08% Simple moving average 200 days-79.06%
Performance Data
Performance Week-22.62% Performance Month-36.75% Performance Quart-37.23% Performance Half-87.69%
Performance Year-87.09% Performance Year-to-date110.8% Volatility daily9.36% Volatility weekly20.93%
Volatility monthly42.89% Volatility yearly148.57% Relative Volume577.63% Average Volume13.41 M
New High New Low

News

2019-04-12 15:00:00 | FINAL DEADLINE: Bronstein, Gewirtz & Grossman, LLC - UXIN, SGYP & MHLD

2019-04-12 14:20:00 | SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Synergy Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-04-12 10:19:00 | FINAL DEADLINE: Bronstein, Gewirtz & Grossman, LLC - UXIN, SGYP & MHLD

2019-04-11 17:23:43 | FRIDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Synergy Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-04-11 16:45:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Synergy Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - SGYP

2019-04-10 11:05:00 | DEADLINE FRIDAY REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Synergy Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-04-09 20:06:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Synergy Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - SGYP

2019-04-09 10:24:00 | SGYP & MHLD - Class Action Bronstein, Gewirtz & Grossman, LLC

2019-04-08 18:28:00 | DEADLINE FRIDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Synergy Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-04-08 14:56:00 | SYNERGY INVESTORS APRIL 12th DEADLINE ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc.; Encourages Investors With Losses In Excess of $100K to Contact the Firm – SGYP

2019-04-07 09:00:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Synergy Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – SGYP

2019-04-05 10:23:00 | Class Action Bronstein, Gewirtz & Grossman, LLC - SGYP & MHLD

2019-04-04 15:10:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Synergy Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - SGYP

2019-04-03 10:22:00 | Class Action Reminder Bronstein, Gewirtz & Grossman, LLC - SGYP & MHLD

2019-04-02 15:35:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Synergy Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - SGYP

2019-03-29 15:00:00 | Bronstein, Gewirtz & Grossman, LLC Class Action Update - UXIN, SGYP & MHLD

2019-03-29 10:57:00 | Bronstein, Gewirtz & Grossman, LLC Class Action Reminder - UXIN, SGYP & MHLD

2019-03-28 14:27:31 | SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Synergy Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – SGYP

2019-03-28 10:57:00 | Bronstein, Gewirtz & Grossman, LLC Class Action Update - UXIN, SGYP & MHLD

2019-03-26 16:15:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Synergy Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - SGYP

2019-03-21 15:00:00 | INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Class Action Against Synergy Pharmaceuticals, Inc. SGYP and Lead Deadline: April 12, 2019

2019-03-21 10:08:00 | INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Class Action Against Synergy Pharmaceutical, Inc. SGYP and Lead Deadline: April 12, 2019

2019-03-19 19:00:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Synergy Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – SGYP

2019-03-19 11:08:00 | SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Class Action Against Synergy Pharmaceutical, Inc. SGYP and Lead Deadline: April 12, 2019

2019-03-15 10:02:00 | SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action Against Synergy Pharmaceutical, Inc. SGYP and Lead Deadline: April 12, 2019

2019-03-14 21:14:50 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Synergy Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – SGYP

2019-03-12 16:57:33 | [$$] Synergy Pharma Bankruptcy Plan Cleared for Creditor Poll

2019-03-11 15:00:00 | SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Announces Class Action Against Synergy Pharmaceutical, Inc. SGYP and Lead Plaintiff Deadline: April 12, 2019

2019-03-11 10:01:00 | SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Announces Class Action Against Synergy Pharmaceutical, Inc. SGYP and Lead Plaintiff Deadline: April 12, 2019

2019-03-07 20:47:59 | Pomerantz Law Firm Announces the Filing of a Class Action on Behalf of Investors in Synergy Pharmaceuticals, Inc. – SGYP

2019-03-06 09:00:00 | Bausch Health Completes Acquisition Of Certain Assets Of Synergy Pharmaceuticals Inc.

2019-03-05 08:04:11 | See what the IHS Markit Score report has to say about Synergy Pharmaceuticals Inc.

2019-03-04 14:12:13 | Chester County to lose 137 pharma jobs

2019-03-01 18:30:00 | Synergy Pharmaceuticals Receives Court Approval for the Sale of Its Assets to Bausch Health

2019-02-28 16:24:43 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Synergy Pharmaceuticals Inc. - SGYP

2019-02-27 08:13:48 | The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings

2019-02-26 18:04:00 | Bausch Health to Acquire Certain Assets of Synergy Pharmaceuticals Inc.

2019-02-26 18:00:00 | Synergy Pharmaceuticals Confirms Bausch Health as Successful Bidder for Its Business Assets

2019-02-26 17:25:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Synergy Pharmaceuticals Inc. - SGYP

2019-02-25 12:35:45 | [$$] Puerto Rico's Debt Saga May Land Back in Washington's Lap

2019-02-22 17:48:17 | [$$] Synergy Pharmaceuticals Wins Approval for Bankruptcy Loan

2019-02-20 18:15:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Synergy Pharmaceuticals Inc. - SGYP

2019-02-20 17:11:00 | Investor Alert: Kaplan Fox Announces Investigation Of Synergy Pharmaceuticals Inc.

2019-02-20 17:08:49 | Bausch Health Companies Inc BHC Q4 2018 Earnings Conference Call Transcript

2019-02-13 15:22:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Synergy Pharmaceuticals Inc. - SGYP

2019-02-13 11:41:57 | [$$] Firm Retention Summary: Synergy Pharmaceuticals Inc.

2019-02-12 11:28:45 | SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Synergy Pharmaceuticals Inc. SGYP

2019-02-11 17:29:58 | SYNERGY PHARMACEUTICALS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that it filed a securities class action lawsuit in the United States District Court for the Eastern District of New York against Synergy Pharmaceuticals, Inc

2019-01-29 08:04:59 | See what the IHS Markit Score report has to say about Synergy Pharmaceuticals Inc.

2019-01-25 08:00:00 | Small Cap Stocks Breaking Out